Coronary heart disease (CHD) is the most common cause of death in the UK. CHD cost the UK National Health Service (NHS) £3.5 billion in 2003. The economic impact of community pharmacists providing a medicines management service for patients with CHD has not been rigorously evaluated; the full economic costs of such interventions are rarely presented in the literature. This paper examines the incremental costs of a 1-year community pharmacistled medicines management service for patients with CHD in the UK, from a healthcare system and patient perspective.